Recently patented and widely used valves for transcatheter aortic valve implantation

Siyamek Neragi-Miandoab, Edvard Skripochnik, Robert E. Michler

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aortic stenosis (AS) is a serious condition in the aging US and European populations. Management of a steno-tic valve is crucial as it can become symptomatic quickly leading to ventricular deterioration and overall poor quality of life. Considering that AS is a disease of the elderly patient population, surgical intervention may not be well tolerated by some patients. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative approach for patients who are unsuitable surgical candidates. Since the first balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA) was implanted by Dr. Cribier, many other valves have been introduced into clinical practice. Self-expanding valves such as the CoreValve ReValving system (Medtronic, Minneapolis, MN) for retrograde implantation and Symetis TX for antegrade and transapical implantation are the most frequently used self-expanding valves. The SAPIEN valve, on the other hand can be implanted both antegrade as well as retrograde. Overall, the most widely used valves are the Edwards SAPIEN and the CoreValve, which have been implanted in more than 40,000 patients worldwide. The Symetis valve has shown promising results in small series in Europe and may be introduced to the US market in the near future. This manuscript will review these 3 recently patented valves and discuss some of the clinical results that are available.

Original languageEnglish (US)
Pages (from-to)196-205
Number of pages10
JournalRecent Patents on Cardiovascular Drug Discovery
Volume7
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Aortic Valve Stenosis
Tics
Population
Quality of Life
Transcatheter Aortic Valve Replacement

Keywords

  • Aortic stenosis
  • Corevalve
  • Sapien valve
  • Symetis
  • Transcatheter aortic valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery

Cite this

Recently patented and widely used valves for transcatheter aortic valve implantation. / Neragi-Miandoab, Siyamek; Skripochnik, Edvard; Michler, Robert E.

In: Recent Patents on Cardiovascular Drug Discovery, Vol. 7, No. 3, 2012, p. 196-205.

Research output: Contribution to journalArticle

@article{93cb4354c3344f0ab6202798a3930431,
title = "Recently patented and widely used valves for transcatheter aortic valve implantation",
abstract = "Aortic stenosis (AS) is a serious condition in the aging US and European populations. Management of a steno-tic valve is crucial as it can become symptomatic quickly leading to ventricular deterioration and overall poor quality of life. Considering that AS is a disease of the elderly patient population, surgical intervention may not be well tolerated by some patients. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative approach for patients who are unsuitable surgical candidates. Since the first balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA) was implanted by Dr. Cribier, many other valves have been introduced into clinical practice. Self-expanding valves such as the CoreValve ReValving system (Medtronic, Minneapolis, MN) for retrograde implantation and Symetis TX for antegrade and transapical implantation are the most frequently used self-expanding valves. The SAPIEN valve, on the other hand can be implanted both antegrade as well as retrograde. Overall, the most widely used valves are the Edwards SAPIEN and the CoreValve, which have been implanted in more than 40,000 patients worldwide. The Symetis valve has shown promising results in small series in Europe and may be introduced to the US market in the near future. This manuscript will review these 3 recently patented valves and discuss some of the clinical results that are available.",
keywords = "Aortic stenosis, Corevalve, Sapien valve, Symetis, Transcatheter aortic valve replacement",
author = "Siyamek Neragi-Miandoab and Edvard Skripochnik and Michler, {Robert E.}",
year = "2012",
doi = "10.2174/157489012803832810",
language = "English (US)",
volume = "7",
pages = "196--205",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Recently patented and widely used valves for transcatheter aortic valve implantation

AU - Neragi-Miandoab, Siyamek

AU - Skripochnik, Edvard

AU - Michler, Robert E.

PY - 2012

Y1 - 2012

N2 - Aortic stenosis (AS) is a serious condition in the aging US and European populations. Management of a steno-tic valve is crucial as it can become symptomatic quickly leading to ventricular deterioration and overall poor quality of life. Considering that AS is a disease of the elderly patient population, surgical intervention may not be well tolerated by some patients. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative approach for patients who are unsuitable surgical candidates. Since the first balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA) was implanted by Dr. Cribier, many other valves have been introduced into clinical practice. Self-expanding valves such as the CoreValve ReValving system (Medtronic, Minneapolis, MN) for retrograde implantation and Symetis TX for antegrade and transapical implantation are the most frequently used self-expanding valves. The SAPIEN valve, on the other hand can be implanted both antegrade as well as retrograde. Overall, the most widely used valves are the Edwards SAPIEN and the CoreValve, which have been implanted in more than 40,000 patients worldwide. The Symetis valve has shown promising results in small series in Europe and may be introduced to the US market in the near future. This manuscript will review these 3 recently patented valves and discuss some of the clinical results that are available.

AB - Aortic stenosis (AS) is a serious condition in the aging US and European populations. Management of a steno-tic valve is crucial as it can become symptomatic quickly leading to ventricular deterioration and overall poor quality of life. Considering that AS is a disease of the elderly patient population, surgical intervention may not be well tolerated by some patients. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative approach for patients who are unsuitable surgical candidates. Since the first balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA) was implanted by Dr. Cribier, many other valves have been introduced into clinical practice. Self-expanding valves such as the CoreValve ReValving system (Medtronic, Minneapolis, MN) for retrograde implantation and Symetis TX for antegrade and transapical implantation are the most frequently used self-expanding valves. The SAPIEN valve, on the other hand can be implanted both antegrade as well as retrograde. Overall, the most widely used valves are the Edwards SAPIEN and the CoreValve, which have been implanted in more than 40,000 patients worldwide. The Symetis valve has shown promising results in small series in Europe and may be introduced to the US market in the near future. This manuscript will review these 3 recently patented valves and discuss some of the clinical results that are available.

KW - Aortic stenosis

KW - Corevalve

KW - Sapien valve

KW - Symetis

KW - Transcatheter aortic valve replacement

UR - http://www.scopus.com/inward/record.url?scp=84870206092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870206092&partnerID=8YFLogxK

U2 - 10.2174/157489012803832810

DO - 10.2174/157489012803832810

M3 - Article

C2 - 23095028

AN - SCOPUS:84870206092

VL - 7

SP - 196

EP - 205

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 3

ER -